αααααβααΎαCHGCF β’ OTCMKTS
add
Chugai Pharmaceutical Co Ltd
32.25$
30 ααααΆ, 8:10:00 PM ααααβααα -5 · USD · OTCMKTS · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΆααα»αααααΆααααααααΆααα·ααααΆαααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
38.76$
α
αααααααααααα
32.25$ - 46.24$
α
ααααααα½αααααΆαα
α»αααααα
29.75$ - 52.22$
ααΎαβαα»αβααΈααααΆα
11.27Β ααααΈααΆα JPY
ααα ααα½αααΌαααααα
8.95ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
TYO
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(JPY) | αααααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 315.68Β αααΈααΆα | 22.40% |
α
αααΆαααααα·ααααα·ααΆα | 71.05Β αααΈααΆα | -2.61% |
α
αααΌααα»ααα | 109.50Β αααΈααΆα | 41.15% |
ααααΆααα
αααααα»ααα | 34.69 | 15.33% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 160.81Β αααΈααΆα | 50.17% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 31.06% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(JPY) | αααααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 845.32Β αααΈααΆα | 36.61% |
ααααααααα»α | 2.07Β ααααΈααΆα | 13.87% |
ααΆαααα½ααα»αααααΌαααα»α | 268.37Β αααΈααΆα | -5.05% |
ααΌαβααααα»α | 1.80Β ααααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 1.65Β αααΈααΆα | β |
ααααααααααΉαααααα
| 0.04 | β |
ααα
ααααααΎαααααα | 19.42% | β |
ααα
ααααααΎααΎααα»α | 22.57% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(JPY) | αααααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 109.50Β αααΈααΆα | 41.15% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 123.64Β αααΈααΆα | 295.09% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -37.57Β αααΈααΆα | -1,986.14% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -69.51Β αααΈααΆα | -3.15% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 10.20Β αααΈααΆα | 130.28% |
ααα αΌαααΆα
αααααΆααααααα | 69.06Β αααΈααΆα | 1,031.87% |
α’αααΈ
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
10 ααΈααΆ 1925
αααααβαααααΆα
αα»ααααα·α
7,604